Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection is a research paper published in Proceedings of the National Academy of Sciences (2023). On theSindex it has a DataRank of 1.2. It has been cited 48 times, with 34 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.584
From this paper's citation signal
Citation Network Contribution
0.604
From 28 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 34 citers.
G. Harold and Leila Y. Mathers Foundation
Grant: Mathers Foundation
UH | Harrington Discovery Institute, University Hospitals
Grant: Harrington Scholar Awards
HHS | National Institutes of Health
Grant: R35 GM131839
HHS | National Institutes of Health
Grant: R01 NS104022
HHS | National Institutes of Health
Grant: S10 OD020012
Larry Ellison Foundation
Grant: Ellison Foundation
Ono Pharmaceutical Foundation
Grant: Breakthrough Science Award
Massachusetts Consortium on Pathogen Readiness
Grant: MassCPR
U.S. Department of Defense
Grant: COVID-19 Expansion for AIRe Program W81XWH2110029
University of Massachusetts Chan Medical School
Grant: COVID-19 Pandemic Fund Pilot
University of Massachusetts Chan Medical School
Grant: Dean's Strategic Development Fund
National Institutes of Health
Grant: 5R01NS104022-07
Expanding the Chemical Diversity of Therapeutic Oligonucleotides
National Institutes of Health
Grant: 1S10OD020012-01
Mid-Scale RNA Synthesis, Purification and Quality Control System
National Institutes of Health
Grant: 5R35GM131839-05
Chemical engineering of therapeutic RNAs for extrahepatic delivery
Fields of Study
Keywords